- Isomorphic Labs has secured $2.1 billion in Series B funding led by Thrive Capital, with backing from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
- The London-based company plans to use the fresh capital to expand its AI drug design engine, accelerate therapeutic programs into clinical stages, and hire top scientific and engineering talent globally.
- Isomorphic Labs could become one of Europe’s most valuable biotech and AI companies.
Isomorphic Labs has landed a massive $2.1 billion Series B round, which the company claims is one of the largest financing deals ever raised by an AI drug discovery company in Europe.
The round was led byThrive Capital and drew support from Alphabet,GV,Temasek,CapitalG, Abu Dhabi-based MGX, and the UK Sovereign AI Fund.
The funding follows the recent speculation that the company eyes over $2 billion in funding. Also, Isomorphic Labs secured $600 million last year to revolutionise AI drug discovery.
Founded in 2021 by DeepMind co-founder and Nobel Prize winner Demis Hassabis, Isomorphic Labs rethinks how medicines are discovered and developed. Headquartered in London, the company also operates from offices in Cambridge and Lausanne.
At the centre of its strategy is IsoDDE, the company’s drug design engine built using multiple foundational models. The platform is designed to predict biological structures and accelerate the discovery of new medicines across different therapeutic areas and drug types.
The company believes this integrated approach could significantly reduce the time and cost involved in bringing new treatments to market. Rather than focusing on a single disease area, Isomorphic Labs is building a broad platform capable of supporting multiple drug programs simultaneously.
Rivals include firms such as Recursion, Meta Flux, and Exscientia, all of which are racing to prove that advanced predictive systems can produce commercially successful medicines faster than traditional methods.
Isomorphic Labs already holds strategic partnerships with major pharmaceutical groups, including Novartis, Eli Lilly and Company, and Johnson & Johnson.
“The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform,” says Ruth Porat, president and chief investment officer of Alphabet and Google.
“We are humbled to have the opportunity to continue to support Isomorphic’s mission to solve all disease. Over the past year, our conviction in the team has only deepened as they’ve made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design,” adds Joshua Kushner, founder and CEO of Thrive Capital.
“The caliber of the team Isomorphic has assembled is unmatched, and they continue to validate our belief that this is the premier group at the intersection of AI and drug discovery. We have strong confidence in Isomorphic. We believe their approach can create important medicines that will be better understood earlier in the process, pushing the boundaries of what’s been possible before,” concludes Dr. Krishna Yeshwant, managing partner at GV.
The fresh funding will be channelled into scaling the company’s proprietary AI drug design engine, IsoDDE, while also accelerating its growing pipeline of therapeutic programs toward clinical trials.
